{{Rsnum
|rsid=7439366
|Gene=UGT2B7
|Chromosome=4
|position=69098620
|Orientation=plus
|GMAF=0.4679
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=UGT2B7
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 21.5 | 55.4 | 23.1
| HCB | 46.7 | 51.1 | 2.2
| JPT | 40.9 | 54.5 | 4.5
| YRI | 98.4 | 1.6 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 46.7 | 51.1 | 2.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}[[rs7439366]], also known as Y268H, is a SNP in the [[UGT2B7]] gene encoding the 2B7 UDP-Glucuronosyltransferase, active primarily in the liver. The [[rs7439366]](C) allele encodes a histidine (H) at amino acid 268, and the (T) allele encodes a tyrosine (Y). Most publications refer to the histidine as the wild-type (more common) allele.

{{PMID|17664247}} In a study of glucuronidation activity of human livers, [[rs7439366]](T;T) individuals had 28% lower activity than [[rs7439366]](C;C) individuals with respect to O-glucuronidation of [[tamoxifen]] metabolites 4-OH-tamoxifen and endoxifen. The authors suggest this may help explain interindividual variability (beyond [[CYP2D6]] variation) in tamoxifen metabolism - and therefore the effectiveness of tamoxifen in reducing [[breast cancer]] recurrence.

{{PharmGKB
|RSID=rs7439366
|Name_s=
|Gene_s=UGT2B7
|Feature=Exon/NonSyn
|Evidence=PubMed ID:18719619
|Annotation=Risk or phenotype-associated allele(s): T/T. Phenotype: Breastfed infants of mothers who are CYP2D6 UMs combined with the UGT2B7*2/*2 are at increased risk of potentially life-threatening CNS depression Study size: 72 mother-child pairs.
|Drugs=codeine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165109702
}}

{{PharmGKB
|RSID=rs7439366
|Name_s=UGT2B7*2; UGT2B7Y; UGT2B7:H268Y; UGT2B7:802C>T
|Gene_s=UGT2B7
|Feature=Exon/NonSyn
|Evidence=PubMed ID:17241877; PubMed ID:17429314; PubMed ID:17978490; PubMed ID:9443856
|Annotation=The impact on glucuronidation activity of the protein is still controvertial; UGT2B7*2 is associated with diclofenac hypatotoxicity; reduced capacity and efficiency of metabolism of carvedilol; associated with higher bladder cancer risk in benzidine-exposed Chinese worker.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145130
}}{{PMID Auto
|PMID=18547414
|Title=Genotyping panel for assessing response to cancer chemotherapy.
|OA=1
}}

{{PMID Auto
|PMID=18622261
|Title=Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.
|OA=1
}}

{{PMID Auto
|PMID=19779319
|Title=CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
|OA=1
}}

{{PMID Auto
|PMID=20973683
|Title=Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.
}}
{{PMID Auto
|PMID=23726609
|Title=Uridine Diphosphate Glucuronosyltransferase 2B7 Variant p.His268Tyr as a Predictor of Kidney Allograft Early Acute Rejection
}}
{{PMID Auto
|PMID=24080498
|Title=Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients
}}{{PMID Auto
|PMID=23130019
|Title=Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations.
|OA=1
}}